Cardiovascular Drugs Practice Questions

Q: Which one of the following is not an adverse effect of ACE inhibitors?

Hypokalemia. **Explanation:** The correct answer is **Hypokalemia**. ACE inhibitors (ACEIs) actually cause **Hyperkalemia**, not hypokalemia. **Mechanism of Action & Correct Option:** ACE inhibitors block the conversion of Angiotensin I to Angiotensin II. Since Angiotensin II is a potent stimulator of **aldosterone** secretion from the adrenal cortex, its inhibition leads to decreased aldosterone levels. Aldosterone normally promotes sodium/water retention and potassium excretion in the distal tubules. Reduced aldosterone results in potassium retention, leading to **hyperkalemia**. This is a high-yield point for NEET-PG, especially when ACEIs are combined with potassium-sparing diuretics or in patients with renal impairment. **Analysis of Incorrect Options:** * **Cough (A):** This is the most common side effect (dry, irritating cough). It is caused by the accumulation of **bradykinin** and substance P in the lungs, as ACE is the enzyme responsible for their degradation. * **Angioneurotic edema (C):** A rare but life-threatening side effect also attributed to increased bradykinin levels. It involves swelling of the lips, tongue, and larynx. * **Skin rash (D):** Common with ACEIs, particularly **Captopril**, often due to its sulfhydryl group. **NEET-PG High-Yield Pearls:** * **Teratogenicity:** ACEIs are contraindicated in pregnancy as they cause fetal renal anomalies (Hypocalvaria). * **First-dose hypotension:** Common in patients on diuretics; start with a low dose at bedtime. * **Bilateral Renal Artery Stenosis:** ACEIs are strictly contraindicated as they can precipitate acute renal failure by reducing efferent arteriolar tone. * **Mnemonic for ACEI side effects (CAPTOPRIL):** **C**ough, **A**ngioedema, **P**roteinuria, **T**aste changes, **O**ther (rash), **P**regnancy contraindication, **R**enal artery stenosis contraindication, **I**ncreased potassium (**Hyperkalemia**), **L**ow BP (First-dose hypotension).

Q: Which drug is used in the management of AV block?

Isoprenaline. **Explanation:** **Correct Option: A. Isoprenaline** Isoprenaline is a potent, non-selective **$̒$-adrenergic agonist** ($̒_1$ and $̒_2$). Its action on $̒_1$ receptors in the heart results in significant positive chronotropic (increased heart rate) and dromotropic (increased conduction velocity) effects [1]. By enhancing conduction through the AV node and increasing the idioventricular rate, it is used as a temporary pharmacological measure to manage high-grade AV block and symptomatic bradycardia until a permanent pacemaker can be inserted [1], [4]. **Analysis of Incorrect Options:** * **B. Dopamine:** While Dopamine has $̒_1$ effects at moderate doses, it is primarily used for cardiogenic or septic shock due to its $̡_1$ (vasoconstriction) and dopaminergic (renal vasodilation) properties [3]. It is not the first-line choice specifically for reversing AV block. * **C. Atropine:** Atropine is an anticholinergic used for sinus bradycardia [2]. While it can improve AV conduction by blocking vagal tone, it is often ineffective in **Type II Second-degree or Third-degree (Complete) AV blocks**, especially if the block is infra-nodal (within the Bundle of His). * **D. Disopyramide:** This is a Class IA antiarrhythmic. It actually **prolongs** the PR interval and can worsen AV block due to its sodium channel blocking properties, making it contraindicated in this condition. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** For acute symptomatic bradycardia/AV block, **Atropine** is usually the initial drug [2], but **Isoprenaline** or **Adrenaline** infusions are preferred if Atropine fails or in cases of high-grade distal blocks [4]. * **Definitive Treatment:** The definitive management for chronic or high-grade AV block is a **Permanent Pacemaker**. * **Isoprenaline Side Effects:** It can cause palpitations, tremors, and may worsen myocardial ischemia by increasing oxygen demand [1].

Q: In shock, what effect does dopamine, in renal doses, have on renal vasculature?

Dilatation of renal vasculature. **Explanation:** Dopamine is a unique catecholamine because its pharmacological effects are strictly **dose-dependent**. Understanding these dose ranges is a high-yield concept for NEET-PG. **1. Why the correct answer is right:** At **low doses (0.5–2 µg/kg/min)**, often referred to as the **"Renal Dose,"** dopamine selectively stimulates **D1 receptors** located in the renal, mesenteric, and coronary vascular beds. Activation of D1 receptors leads to an increase in intracellular cAMP, resulting in **vasodilation of the renal vasculature**. This increases renal blood flow and glomerular filtration rate (GFR), promoting diuresis and natriuresis. **2. Why the incorrect options are wrong:** * **Option A:** While dopamine can decrease total peripheral resistance at intermediate doses (via β2 stimulation), "renal dose" specifically targets D1 receptors for localized renal vasodilation, not systemic reduction in resistance. * **Option B:** Constriction occurs at **high doses (>10 µg/kg/min)** due to **α1 receptor** stimulation. This causes systemic vasoconstriction, which can actually decrease renal perfusion. * **Option D:** Increase in cardiac output is the primary effect of **intermediate doses (2–10 µg/kg/min)**, where **β1 receptor** stimulation increases myocardial contractility (inotropy) and heart rate (chronotropy). **NEET-PG High-Yield Pearls:** * **Dopamine Dose Summary:** Low (D1: Vasodilation) → Mid (β1: Inotropy) → High (α1: Vasoconstriction). * **Fenoldopam:** A selective D1 agonist used in hypertensive emergencies to maintain renal perfusion. * **Clinical Note:** Current guidelines (like SSC) suggest that "low-dose dopamine" does not significantly improve outcomes in acute renal failure compared to placebo, though it remains a classic pharmacological concept for exams.

Q: Which beta-blocker lacks local anesthetic effect?

Atenolol. **Explanation:** The "local anesthetic effect" of beta-blockers is also known as **Membrane Stabilizing Activity (MSA)**. This property is due to the blockade of voltage-gated sodium channels, similar to the mechanism of lidocaine. Drugs with high MSA can cause decreased corneal sensitivity (when used topically) and are more toxic in overdose due to cardiac conduction delays. **1. Why Atenolol is correct:** Atenolol is a **hydrophilic (water-soluble)**, cardioselective beta-1 blocker. It completely lacks membrane stabilizing activity (MSA). Because it is hydrophilic, it also has poor CNS penetration, leading to fewer side effects like nightmares or depression. **2. Why the other options are incorrect:** * **Metoprolol:** This is a cardioselective beta-blocker that possesses **weak but present** membrane stabilizing activity. * **Pindolol:** This is a non-selective beta-blocker with **significant** membrane stabilizing activity. It is also notable for having Intrinsic Sympathomimetic Activity (ISA). **High-Yield Clinical Pearls for NEET-PG:** * **Strongest MSA:** **Propranolol** has the highest membrane stabilizing activity (making it dangerous in overdose due to QRS widening). * **Beta-blockers with MSA:** Propranolol, Pindolol, Acebutolol, Metoprolol, and Labetalol. * **Beta-blockers WITHOUT MSA:** **Atenolol**, Sotalol, Timolol, and Nadolol. * **Clinical Significance:** Beta-blockers with MSA (like Propranolol) should never be used as eye drops for glaucoma because they would anesthetize the cornea, leading to a loss of the protective blink reflex and potential corneal ulceration. **Timolol** is preferred in glaucoma because it lacks MSA.

Q: What is the mechanism of action of digitalis?

Decrease in heart rate with decrease in oxygen consumption. **Mechanism of Action of Digitalis (Digoxin)** The therapeutic effect of digitalis in heart failure is unique because it increases cardiac output while simultaneously reducing the workload of the heart. **Why Option D is Correct:** 1. **Decrease in Heart Rate:** Digitalis exerts a **vagomimetic effect** (parasympathetic activation) and slows conduction through the AV node. This increases the diastolic filling time, leading to a decrease in heart rate (negative chronotropy). 2. **Decrease in Oxygen Consumption ($MVO_2$):** Although digitalis is a positive inotrope (it increases force of contraction by inhibiting the $Na^+/K^+$ ATPase pump), in a failing heart, it significantly **reduces ventricular wall tension** and heart size (Laplace’s Law). The reduction in heart rate and wall tension outweighs the energy cost of increased contractility, leading to a net **decrease** in myocardial oxygen demand. **Analysis of Incorrect Options:** * **Options A & B:** These are incorrect because digitalis is a **negative chronotrope**. It decreases heart rate, making it useful in controlling ventricular rate in atrial fibrillation. * **Option C:** While digitalis does decrease heart rate, it does not increase oxygen consumption in a failing heart. Drugs that increase both contractility and oxygen consumption (like Dobutamine) can worsen ischemia, whereas digitalis is more "oxygen-efficient" in the context of heart failure. **NEET-PG High-Yield Pearls:** * **Molecular Target:** Reversible inhibition of the **$Na^+/K^+$ ATPase pump** on the sarcolemma. * **ECG Changes:** Characterized by the **"Reverse Tick"** or "Sagging" ST-segment depression (Salvador Dali mustache sign). * **Electrolyte Interaction:** **Hypokalemia** predisposes to digitalis toxicity because $K^+$ and Digoxin compete for the same binding site on the ATPase pump. * **Antidote:** Digoxin-specific antibody fragments (**DigiFab**).

Q: A premature infant is born with a patent ductus arteriosus. Its closure can be stimulated by administration of:

Prostaglandin inhibitors. **Explanation:** The patency of the **Ductus Arteriosus (DA)** in utero is actively maintained by high levels of circulating **Prostaglandins (specifically PGE2)**, which are produced by the placenta and the ductal tissue itself. PGE2 acts on EP4 receptors to cause vasodilation of the ductal smooth muscle. **Why the correct answer is right:** At birth, PGE2 levels normally fall, leading to functional closure of the ductus. In premature infants, if the ductus remains patent (PDA), pharmacological closure can be achieved by administering **Prostaglandin Inhibitors**, specifically non-selective **NSAIDs** like **Indomethacin** or **Ibuprofen**. These drugs inhibit the enzyme Cyclooxygenase (COX), thereby decreasing PGE2 synthesis and allowing the ductus to constrict and close. **Why the incorrect options are wrong:** * **A. Prostaglandin analogue:** Administering PGE1 (Alprostadil) would keep the ductus *open*. This is clinically indicated in cyanotic heart diseases (e.g., Transposition of Great Arteries) where a PDA is life-saving. * **B & C. Estrogen/Anti-estrogen:** These hormonal compounds have no direct physiological role in the acute contraction or relaxation of the ductus arteriosus smooth muscle. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** While Indomethacin was the traditional gold standard, **Ibuprofen** is often preferred now due to a lower risk of renal side effects and necrotizing enterocolitis (NEC). * **Alternative:** Recent studies suggest **Paracetamol (Acetaminophen)** is also effective for PDA closure with fewer side effects. * **Mnemonic:** To **K**eep the ductus open, give PGE (Alprostadil). To **C**lose it, give **C**OX inhibitors (Indomethacin).

Q: Oral sacubitril is approved for the treatment of which condition?

Congestive cardiac failure. **Explanation:** **Sacubitril** is a first-in-class **Neprilysin inhibitor**. It is primarily used in combination with Valsartan (an Angiotensin Receptor Blocker) as an **ARNI** (Angiotensin Receptor-Neprilysin Inhibitor) for the management of **Congestive Cardiac Failure (CCF)**, specifically Heart Failure with reduced Ejection Fraction (HFrEF). * **Mechanism of Action:** Neprilysin is an enzyme responsible for the degradation of beneficial endogenous vasoactive peptides, such as **Atrial Natriuretic Peptide (ANP)** and **B-type Natriuretic Peptide (BNP)**. By inhibiting neprilysin, sacubitril increases the levels of these peptides, leading to vasodilation, natriuresis (sodium excretion), and diuresis, while reducing sympathetic tone and cardiac fibrosis. * **Why Valsartan is added:** Neprilysin also degrades Angiotensin II. Therefore, inhibiting neprilysin alone would increase Angiotensin II levels. Adding Valsartan counteracts this effect, providing a synergistic benefit in heart failure patients. **Analysis of Incorrect Options:** * **B. IBS with diarrhea:** Sacubitril has no role here. Eluxadoline or Alosetron are drugs used in IBS-D. * **C. Unstable Angina:** Treatment involves antiplatelets, anticoagulants, and nitrates. Sacubitril is not indicated for acute coronary syndromes. * **D. Vitamin K deficiency:** This is managed with Vitamin K1 (Phytonadione) supplementation. **High-Yield Clinical Pearls for NEET-PG:** * **PARADIGM-HF Trial:** The landmark study that established ARNI superiority over Enalapril in reducing mortality in HFrEF. * **Washout Period:** When switching from an ACE inhibitor to Sacubitril/Valsartan, a **36-hour washout period** is mandatory to prevent the risk of **angioedema** (as both drugs increase bradykinin). * **Contraindication:** Do not use in patients with a history of angioedema related to previous ACEI/ARB therapy.

Q: Which antihypertensive medication is safe to use in patients with renal disease?

Amlodipine. **Explanation:** **Amlodipine** is a long-acting Dihydropyridine Calcium Channel Blocker (CCB). It is considered safe and often preferred in patients with renal disease because it is primarily metabolized by the **liver** and does not require dose adjustment in renal impairment. Furthermore, CCBs do not adversely affect the Glomerular Filtration Rate (GFR) or electrolyte balance, unlike other antihypertensives. **Analysis of Incorrect Options:** * **Atenolol:** This is a hydrophilic beta-blocker that is primarily excreted unchanged by the **kidneys**. In patients with renal failure, it can accumulate, leading to severe bradycardia and toxicity. (Note: Metoprolol is preferred over Atenolol in renal disease as it is hepatically metabolized). * **Thiazides:** These diuretics lose their efficacy when the GFR falls below **30 mL/min**. In advanced renal disease, they are ineffective as antihypertensives (Loop diuretics like Furosemide are used instead). * **Methyldopa:** While used in pregnancy-induced hypertension, it is not a first-line drug for renal patients. Its metabolites are renally cleared, and it can cause significant sedation and central side effects in patients with uremia. **High-Yield Clinical Pearls for NEET-PG:** 1. **DOC for Hypertensive Diabetic Nephropathy:** ACE inhibitors (e.g., Enalapril) or ARBs (e.g., Losartan) are the drugs of choice due to their **renoprotective** effects (dilating the efferent arteriole), provided serum creatinine is <3 mg/dL. 2. **Safe Beta-blockers in Renal Failure:** Metoprolol, Propranolol, and Labetalol (Hepatic metabolism). 3. **Safe Statins in Renal Failure:** Atorvastatin (does not require dose adjustment). 4. **Avoid in Bilateral Renal Artery Stenosis:** ACE inhibitors/ARBs, as they can precipitate acute renal failure.

Q: Regarding lidocaine, all of the following are true EXCEPT:

Dose needs to be altered in renal failure. Lidocaine is a Class IB antiarrhythmic primarily used for ventricular arrhythmias, especially post-myocardial infarction. **Explanation of the Correct Answer (A):** Lidocaine is primarily metabolized by the **liver** via the CYP450 system (specifically CYP1A2 and CYP3A4) into active metabolites like monoethylglycinexylidide (MEGX). Its clearance is highly dependent on hepatic blood flow. Therefore, dose adjustments are crucial in **hepatic failure** or congestive heart failure (due to reduced liver perfusion), but **not in renal failure**, as the kidneys play a negligible role in its primary clearance. **Analysis of Other Options:** * **B. Loading dose is given before infusion:** Lidocaine has a short half-life (approx. 1.5–2 hours). To achieve rapid therapeutic plasma concentrations (1.5–5 µg/mL), a loading dose is mandatory before starting a continuous maintenance infusion. * **C. Little affected by heat and pH:** Lidocaine is a stable compound. Unlike some other local anesthetics, it is relatively resistant to heat (autoclavable) and maintains stability across a reasonable range of pH, though its lipid solubility (and thus onset) is influenced by tissue pH. * **D. It prolongs the refractory period:** While Class IB agents typically shorten the Action Potential Duration (APD) in healthy tissue, they **prolong the Effective Refractory Period (ERP) relative to the APD** in ischemic or depolarized myocardial tissue. This selective action helps suppress ectopic foci. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Lidocaine is no longer the first-line drug for stable VT (Amiodarone is preferred), but it remains an alternative in ACLS protocols. * **Toxicity:** CNS side effects are most common (dizziness, seizures, "Lidocaine crazies"). * **Route:** It undergoes extensive first-pass metabolism; hence, it is **never given orally**.

Q: In an established case of coronary artery disease post myocardial infarction, which of the following drugs will not prolong life expectancy?

Nitrate. **Explanation:** In the management of post-Myocardial Infarction (MI) patients, drugs are categorized into those that provide **symptomatic relief** and those that provide a **mortality benefit** (prolong life expectancy). **Why Nitrates are the correct answer:** Nitrates (e.g., Nitroglycerin, Isosorbide mononitrate) act primarily as venodilators, reducing preload and myocardial oxygen demand. While they are highly effective in relieving anginal pain and managing acute pulmonary edema, they **do not reduce mortality** or prevent future cardiac events in stable post-MI patients. They are purely symptomatic treatments. **Why the other options are incorrect:** * **ACE Inhibitors (e.g., Enalapril, Ramipril):** These prevent "ventricular remodeling" (pathological thinning and dilation of the heart wall) post-MI. They significantly reduce mortality, especially in patients with reduced ejection fraction. * **Statins (e.g., Atorvastatin):** Beyond lowering LDL, statins have "pleiotropic effects" such as stabilizing atherosclerotic plaques and reducing inflammation, which prevents recurrent MI and extends life. * **Aspirin:** As an antiplatelet agent, it prevents thrombus formation on disrupted plaques. It is a cornerstone of secondary prevention that significantly reduces the risk of re-infarction and death. **High-Yield Clinical Pearls for NEET-PG:** 1. **Mortality-reducing drugs post-MI:** Beta-blockers, ACE inhibitors/ARBs, Statins, Aspirin, and Aldosterone antagonists (e.g., Eplerenone). 2. **Nitrate Contraindication:** Never co-administer nitrates with Sildenafil (PDE-5 inhibitors) due to the risk of severe, fatal hypotension. 3. **Nitrate Tolerance:** Continuous use leads to tachyphylaxis; a "nitrate-free interval" of 8–12 hours (usually at night) is required to maintain efficacy.

Question 1

Which one of the following is not an adverse effect of ACE inhibitors?

Accepted Answer

Hypokalemia

Answer

Cough

Answer

Angioneurotic edema

Answer

Skin rash

Question 2

Which drug is used in the management of AV block?

Accepted Answer

Isoprenaline

Answer

Dopamine

Answer

Atropine

Answer

Disopyramide

Question 3

In shock, what effect does dopamine, in renal doses, have on renal vasculature?

Accepted Answer

Dilatation of renal vasculature

Answer

Reduction in peripheral resistance

Answer

Constriction of renal vasculature

Answer

Increase in cardiac output

Question 4

Which beta-blocker lacks local anesthetic effect?

Accepted Answer

Atenolol

Answer

Metoprolol

Answer

Pindolol

Answer

All of the above

Question 5

What is the mechanism of action of digitalis?

Accepted Answer

Decrease in heart rate with decrease in oxygen consumption

Answer

Increase in heart rate with increase in oxygen consumption

Answer

Increase in heart rate without increase in oxygen consumption

Answer

Decrease in heart rate with increase in oxygen consumption

Question 6

A premature infant is born with a patent ductus arteriosus. Its closure can be stimulated by administration of:

Accepted Answer

Prostaglandin inhibitors

Answer

Prostaglandin analogue

Answer

Estrogen

Answer

Anti-estrogen compounds

Question 7

Oral sacubitril is approved for the treatment of which condition?

Accepted Answer

Congestive cardiac failure

Answer

IBS with diarrhea predominance

Answer

Unstable angina

Answer

Vitamin K deficiency

Question 8

Which antihypertensive medication is safe to use in patients with renal disease?

Accepted Answer

Amlodipine

Answer

Atenolol

Answer

Thiazide

Answer

Methyldopa

Question 9

Regarding lidocaine, all of the following are true EXCEPT:

Accepted Answer

Dose needs to be altered in renal failure

Answer

Loading dose is given before infusion

Answer

It is little affected by heat and pH

Answer

It prolongs the refractory period

Question 10

In an established case of coronary artery disease post myocardial infarction, which of the following drugs will not prolong life expectancy?

Accepted Answer

Nitrate

Answer

ACE inhibitors

Answer

Statin

Answer

Aspirin

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?